-$0.08 EPS Expected for Opko Health Inc. (OPK) This Quarter

Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will post ($0.08) earnings per share for the current quarter, according to Zacks. Three analysts have provided estimates for Opko Health’s earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.10). Opko Health reported earnings per share of ($0.12) during the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The company is scheduled to report its next earnings report on Thursday, March 7th.

On average, analysts expect that Opko Health will report full year earnings of ($0.21) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.17). For the next fiscal year, analysts expect that the business will report earnings of ($0.20) per share, with EPS estimates ranging from ($0.34) to ($0.09). Zacks’ earnings per share averages are a mean average based on a survey of research firms that cover Opko Health.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. The firm had revenue of $250.00 million during the quarter, compared to the consensus estimate of $264.04 million. During the same quarter in the prior year, the firm posted ($0.08) EPS. The business’s revenue was up 1.6% on a year-over-year basis.

OPK has been the topic of a number of analyst reports. BidaskClub cut Opko Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 16th. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price target on shares of Opko Health in a research note on Tuesday, August 7th. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Friday. Barrington Research restated a “buy” rating and issued a $7.00 price target on shares of Opko Health in a research note on Monday, November 12th. Finally, ValuEngine upgraded Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, September 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Opko Health currently has a consensus rating of “Buy” and a consensus target price of $9.50.

Shares of Opko Health stock traded down $0.02 on Wednesday, reaching $3.72. 1,882,472 shares of the company were exchanged, compared to its average volume of 4,021,159. Opko Health has a one year low of $2.66 and a one year high of $6.40. The stock has a market cap of $2.09 billion, a P/E ratio of -12.83 and a beta of 1.90. The company has a quick ratio of 0.78, a current ratio of 0.91 and a debt-to-equity ratio of 0.03.

In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction on Friday, September 7th. The shares were purchased at an average price of $5.57 per share, for a total transaction of $55,700.00. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 42.74% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. BlackRock Inc. grew its holdings in shares of Opko Health by 38.7% during the 2nd quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares in the last quarter. First Manhattan Co. grew its holdings in shares of Opko Health by 4,664.8% during the 3rd quarter. First Manhattan Co. now owns 4,290,713 shares of the biotechnology company’s stock worth $14,845,000 after purchasing an additional 4,200,663 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Opko Health by 129.9% during the 2nd quarter. Northern Trust Corp now owns 4,025,496 shares of the biotechnology company’s stock worth $18,920,000 after purchasing an additional 2,274,820 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Opko Health by 199,980.6% during the 3rd quarter. Panagora Asset Management Inc. now owns 1,482,597 shares of the biotechnology company’s stock worth $5,130,000 after purchasing an additional 1,481,856 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Opko Health by 25.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock worth $15,363,000 after purchasing an additional 897,406 shares in the last quarter. Hedge funds and other institutional investors own 26.20% of the company’s stock.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Further Reading: Benefits of owning preferred stock

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit